Stockscreener 앱 받기
6.32
3.61%
0.22
시간 외 거래:
6.39
0.07
+1.11%
전일 마감가:
$6.10
열려 있는:
$6.22
하루 거래량:
2.41M
Relative Volume:
1.04
시가총액:
$582.56M
수익:
$823.60M
순이익/손실:
$-116.00M
주가수익비율:
-4.8615
EPS:
-1.3
순현금흐름:
$-107.30M
1주 성능:
+61.64%
1개월 성능:
+13.87%
6개월 성능:
-49.07%
1년 성능:
-77.16%
1일 변동 폭
$6.05
$6.40
1주일 범위
$3.85
$6.40
52주 변동 폭
$3.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.32 | 527.88M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - uk.finance.yahoo.com
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet and Other Big Stocks Record Gains on Wednesday - AInvest
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings - AInvest
Myriad Genetics shares surge 30.49% in premarket after reporting strong Q2 earnings and raising 2025 revenue guidance. - AInvest
Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance - AInvest
MYRIAD GENETICS INC SEC 10-Q Report - TradingView
Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts - GuruFocus
Myriad Genetics: Leveraging Strategic Overhaul and Market Tailwinds for a Comeback in Precision Medicine - AInvest
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth - AInvest
Myriad Genetics Aims for High Single-Digit to Low Double-Digit Growth through Cancer Care Continuum Focus. - AInvest
Myriad Genetics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Updates 2025 Revenue Guidance Amid Growth - TipRanks
Myriad Genetics (MYGN) Q2 Revenue Up 6% - AOL.com
Myriad Genetics Surges After Hours on Strong Q2 Earnings and Raised Revenue Guidance - AInvest
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - inkl
Hold Rating Maintained for Myriad Genetics Amid Mixed Performance and Strategic Challenges - TipRanks
Myriad Genetics Edges Past Estimates And Lifts Revenue Outlook - Finimize
Earnings call transcript: Myriad Genetics beats Q2 2025 expectations with revenue growth - Investing.com Canada
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics - Nasdaq
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - sg.finance.yahoo.com
Myriad Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Myriad: Q2 Earnings Snapshot - San Francisco Chronicle
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c) - TipRanks
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com
Myriad Genetics Reports Q2 Revenue Ahead of Estimates, Stock Jumps 30.6% - AInvest
Myriad Genetics earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% - Yahoo Finance
Myriad Genetics Q2 revenue up 1% YoY, raises FY23 guidance. - AInvest
Myriad Genetics Reports Second Quarter 2025 Financial - GlobeNewswire
[8-K] Myriad Genetics Inc Reports Material Event | MYGN SEC FilingForm 8-K - Stock Titan
Prenatal care is evolving with Myriad - WFLA
Price Channel Expanding on Myriad Genetics Inc.’s ChartLow Risk Equity Screener With Results Shared - metal.it
Myriad Genetics Inc. Recovery Likely Here’s What Data ShowsLow Risk Swing Trade Opportunities Identified - metal.it
Myriad Genetics Q2 2025 Earnings: A Pivotal Moment for a Cash-Burning Biotech - AInvest
Earnings To Watch: Myriad Genetics (MYGN) Reports Q2 Results Tomorrow - Yahoo Finance
How strong is Myriad Genetics Inc. company’s balance sheetSuperior profit margins - Jammu Links News
How does Myriad Genetics Inc. generate profit in a changing economyExponential wealth increase - Jammu Links News
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):